Abbvie Inc
NYSE: ABBV
$175.17
-$3.33 (-1.9%)
Closing Price on January 10, 2025
ABBV Articles
AbbVie reported mixed third-quarter financial results and a dividend hike before the markets opened on Friday.
Published:
Last Updated:
Four companies in four very different sectors that all offer liquidity, a degree of safety and solid dividends that should continue to rise.
Published:
Last Updated:
The October 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
Published:
Last Updated:
Earnings season is now in full swing, and we have put together a preview of Bristol-Myers, AbbVie and some of the other top players in the health care sector.
Published:
Last Updated:
A new Jefferies research report features top pharmaceutical picks for the fourth quarter. Any of these top picks make good sense for long-term growth and income portfolios.
Published:
Last Updated:
The September 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest was mixed.
Published:
Last Updated:
In a new research report from Jefferies, many of the outstanding companies in pharmaceuticals and biotech space show up among the stocks to buy.
Published:
Last Updated:
Any of these three top pharmaceutical companies makes an outstanding addition to more conservative portfolios. They are also far less volatile and act better than biotechs if the market gets dicey.
Published:
Last Updated:
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
Published:
Last Updated:
In a recent research note, the analysts at Jefferies make a big move by adding a top technology company to the firm's well respected Franchise Picks list of stocks to Buy.
Published:
Last Updated:
In a time when government wrangling about drug prices is more than commonplace, news of a biosimilar for the mega-blockbuster Humira being approved took the backseat to many other things.
Published:
Last Updated:
Most Wall Street strategists agree that the way to play the fourth quarter and next year is with large cap stocks that pay and consistently increase their dividends.
Published:
Last Updated:
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
Published:
Last Updated:
The August 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Apple, Callon Petroleum, Hewlett Packard Enterprise, Lululemon Athletica, Nike and Rio Tinto.
Published:
Last Updated:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.